Clarivate Plc has agreed to sell its Life Sciences & Healthcare segment to Altaris LLC for $600 million, aiming to sharpen its focus on AI-driven intelligence in Academia & Government and Intellectual Property segments. The sale will improve Clarivate's financial profile by enhancing revenue mix, expanding EBITDA margins, and reducing capital intensity, with proceeds used to reduce debt. The transaction is expected to close by year-end, and Clarivate reaffirmed its 2026 financial outlook including the divested segment's results classified as discontinued operations from Q3. This strategic move positions Clarivate as a more focused leader in knowledge and innovation economy sectors.
Christopher Derrick, known for writing on Star Trek: Picard and The Equalizer, premieres his first film as sole writer-director, Moral Dirt, at the Academy Award® Qualifying LA Shorts International Film Festival on August 3, 2026. The 15-minute psych...
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His additio...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
